Mesa Laboratories, Inc. - Common Stock (MLAB)
Healthcare › Industrial Instruments For Measurement, Display, and Control
Price History
Feb 9, 2026 — Mar 31, 2026Investment Snapshot
- Trading 139% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 4.9% — below-average profitability
- Revenue growing at 11% annually
Mesa Laboratories, Inc. - Common Stock (MLAB) is a Healthcare company operating in Industrial Instruments For Measurement, Display, and Control, listed on the NASDAQ , with a market capitalisation of $470 million . Key value metrics: P/E ratio 51.2, P/B ratio 2.52, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Mesa Laboratories, Inc. - Common Stock — Fundamental Analysis Summary
Mesa Laboratories, Inc. - Common Stock (MLAB) is currently trading 139% above its Graham Number of $35.53, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 51.2x.
On financial health, MLAB shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 4.9% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.37.
StockPik's composite Value Score for MLAB is 74/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MLAB reports a high gross margin of 62.8% (sector average: 33.5%) and a modest operating margin of 8.7%.
MLAB shows revenue growing at 11% year-over-year, with earnings growing at 99%.
MLAB pays a modest dividend yield of 0.8%.